AC Immune Appoints Renowned Neurologist Catherine Mummery as Chair of Clinical Advisory Board

Core Insights - AC Immune SA has appointed Prof. Catherine Mummery as Chairwoman of its Clinical Advisory Board, bringing extensive experience in dementia clinical trials and neurodegenerative diseases [2][5][6] Company Overview - AC Immune is a clinical-stage biopharmaceutical company focused on precision therapeutics for neurodegenerative diseases, including Alzheimer's and Parkinson's diseases [2][8] - The company utilizes two validated technology platforms, SupraAntigen® and Morphomer®, to develop a diverse pipeline of therapeutic and diagnostic programs [8][10] Leadership and Expertise - Prof. Mummery has led over 20 early-stage studies on disease-modifying agents in dementia and has been involved in significant clinical trials, including AC Immune's ACI-35.030 [4][5] - The Clinical Advisory Board (CAB) includes other notable experts in the field, enhancing the company's strategic clinical development and regulatory advice [6][8] Clinical Development Focus - The company is advancing its pipeline of active immunotherapies, with several candidates in Phase 2 development and novel therapeutics targeting intracellular mechanisms of neurodegenerative diseases [5][9] - Prof. Mummery expressed enthusiasm for leading the CAB as the company approaches critical milestones in clinical trials [5][9]